What happened with PTHS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pelthos Therapeutics sells prescription medicines, with most revenue coming from ZELSUVMI. This FDA-approved topical treatment for molluscum contagiosum can be applied by patients or caregivers outside a medical setting. National and regional wholesalers buy the drug from Pelthos and supply pharmacies that dispense it to patients. The company also owns FDA-approved XEPI for impetigo and XEGLYZE for head lice, but their commercial launches remain planned and require manufacturing, supply-chain and regulatory preparation.
ZELSUVMI is still early in commercialization. Sales depend on physicians prescribing it, patients choosing treatment and insurers covering the cost. Pelthos also relies on a limited group of wholesalers for access to the market. It makes the drug’s active ingredient at its own facility, while Orion Corporation manufactures the finished medicine; raw materials come from a limited pool of suppliers.
Pelthos’s rights to ZELSUVMI depend on an exclusive license from Ligand, which carries royalty and other obligations. That license allows Pelthos to seek approval and commercialize the medicine worldwide except Japan.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Pelthos’s results hinge on ZELSUVMI adoption and reliable finished-product supply from its contracted manufacturer, Orion Corporation.
Pelthos depends on Ligand Pharmaceuticals for the technology and intellectual property behind ZELSUVMI, while Ligand holds a substantial stake in Pelthos and receives 13% of the drug’s worldwide sales as royalties. Ligand earns revenue by funding medicines and licensing technology to drug companies; its ZELSUVMI royalty revenue offers a read on adoption of Pelthos’s molluscum contagiosum treatment.
Ligand Pharmaceuticals Inc. earningsLGND
Ligand receives royalties from worldwide ZELSUVMI sales, so any separately disclosed royalty revenue in its report will show whether sales of the treatment are expanding.
Look for ZELSUVMI-specific royalties and how they change. Rising royalties mean the drug is generating more royalty income; flat or falling royalties suggest sales have not expanded. Ligand's overall results include other business, so total revenue or earnings per share alone cannot show how ZELSUVMI is selling.
Pelthos Therapeutics Inc. earningsThis company
Pelthos Therapeutics depends on ZELSUVMI for product sales, and this report will show how much U.S. sales bring in after discounts and rebates and what it costs to supply the drug.
Read ZELSUVMI net product revenue alongside the cost of goods sold. Revenue growing faster than those costs would show that more sales are translating into commercial returns; weak revenue, or costs rising faster, would mean demand is not yet yielding enough and supply and commercialization still consume resources.
